T1	CHEM 64 84	brentuximab vedotina
#1	AnnotatorNotes T1	C2973446; brentuximab vedotin; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T2	PROC 87 90	CHP
#2	AnnotatorNotes T2	C0278651; cyclophosphamide/doxorubicin/prednisone; Therapeutic or Preventive Procedure
T3	PROC 95 99	CHOP
#3	AnnotatorNotes T3	C0163868; CHOP regimen; Therapeutic or Preventive Procedure
T4	PROC 105 125	tratamiento estandar
#4	AnnotatorNotes T4	C2936643; Standard of Care; Health Care Activity
T5	DISO 143 172	linfomas de células T maduras
#5	AnnotatorNotes T5	C0079774; Peripheral T-Cell Lymphoma; Neoplastic Process
T6	PROC 210 281	Estudio de fase III, aleatorizado, doble ciego y controlado con placebo
T7	PROC 316 319	CHP
#6	AnnotatorNotes T7	C0278651; cyclophosphamide/doxorubicin/prednisone; Therapeutic or Preventive Procedure
T8	CHEM 286 306	brentuximab vedotina
#7	AnnotatorNotes T8	C2973446; brentuximab vedotin; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T9	PROC 309 312	CHP
#8	AnnotatorNotes T9	C0278651; cyclophosphamide/doxorubicin/prednisone; Therapeutic or Preventive Procedure
T10	PROC 340 344	CHOP
#9	AnnotatorNotes T10	C0163868; CHOP regimen; Therapeutic or Preventive Procedure
T11	PROC 350 378	tratamiento de primera línea
#10	AnnotatorNotes T11	C1708063; First line treatment; Therapeutic or Preventive Procedure
T12	DISO 386 415	linfomas de células T maduras
#11	AnnotatorNotes T12	C0079774; Peripheral T-Cell Lymphoma; Neoplastic Process
T13	DISO 454 483	Linfomas de células T maduras
#12	AnnotatorNotes T13	C0079774; Peripheral T-Cell Lymphoma; Neoplastic Process
T14	DISO 617 637	lesiones mensurables
T15	PROC 653 656	TAC
#13	AnnotatorNotes T15	C0040405; X-Ray Computed Tomography; Diagnostic Procedure
T16	PROC 679 690	diagnóstico
#14	AnnotatorNotes T16	C0011900; Diagnosis; Diagnostic Procedure
T17	DISO 694 722	linfoma de células T maduras
#15	AnnotatorNotes T17	C0079774; Peripheral T-Cell Lymphoma; Neoplastic Process
T18	DISO 766 779	Encefalopatía
#16	AnnotatorNotes T18	C0006111; Brain Diseases; Disease or Syndrome | C0085584; Encephalopathies; Disease or Syndrome
T19	DISO 814 832	proceso neoplásico
#17	AnnotatorNotes T19	C0027671; Neoplastic Processes; Neoplastic Process
T20	PROC 835 846	Diagnóstico
#18	AnnotatorNotes T20	C0011900; Diagnosis; Diagnostic Procedure
T21	DISO 857 885	trastorno linfoproliferativo
#19	AnnotatorNotes T21	C0024314; Lymphoproliferative Disorders; Neoplastic Process
T22	DISO 888 925	linfoma cutáneo primario de células T
#20	AnnotatorNotes T22	C0079773; Lymphoma, T-Cell, Cutaneous; Neoplastic Process
T23	DISO 943 959	micosis fungoide
#21	AnnotatorNotes T23	C0026948; Mycosis Fungoides; Neoplastic Process
T24	DISO 984 1002	neoplasia primaria
T25	DISO 1013 1035	neoplasia hematológica
T26	DISO 1038 1062	síndrome mielodisplásico
#22	AnnotatorNotes T26	C0026985; Myelodysplasia; Congenital Abnormality | C3463824; MYELODYSPLASTIC SYNDROME; Neoplastic Process
T27	DISO 1119 1159	leucoencefalopatía multifocal progresiva
#23	AnnotatorNotes T27	C0023524; Leukoencephalopathy, Progressive Multifocal; Disease or Syndrome
T28	DISO 1161 1164	LMP
#24	AnnotatorNotes T28	C0023524; Leukoencephalopathy, Progressive Multifocal; Disease or Syndrome
T29	ANAT 155 164	células T
#25	AnnotatorNotes T29	C0039194; T-Lymphocyte; Cell
T30	ANAT 398 407	células T
#26	AnnotatorNotes T30	C0039194; T-Lymphocyte; Cell
T31	ANAT 466 475	células T
#27	AnnotatorNotes T31	C0039194; T-Lymphocyte; Cell
T32	CHEM 610 613	FDG
#28	AnnotatorNotes T32	C4553797; Fluorodeoxyglucose; Organic Chemical
T33	ANAT 705 714	células T
#29	AnnotatorNotes T33	C0039194; T-Lymphocyte; Cell
T34	ANAT 896 903	cutáneo
#30	AnnotatorNotes T34	C0011646; Dermis; Tissue | C1123023; Skin; Body System
T35	ANAT 916 925	células T
#31	AnnotatorNotes T35	C0039194; T-Lymphocyte; Cell
T36	DISO 782 794	meningopatía
T37	CHEM 589 608	fluorodesoxiglucosa
#32	AnnotatorNotes T37	C4553797; Fluorodeoxyglucose; Organic Chemical
T38	Date 13 17	2012
T39	LIVB 129 138	pacientes
#33	AnnotatorNotes T39	C0030705; Patients; Patient or Disabled Group
T42	LIVB 659 668	Pacientes
#34	AnnotatorNotes T42	C0030705; Patients; Patient or Disabled Group
T43	Date 847 853	actual
T44	Neg_cue 1067 1069	no
T45	Duration 1076 1087	>o = 3 años
T46	PROC 173 177	CD30
#35	AnnotatorNotes T46	C3888510; CD30 expression; Laboratory Procedure
T47	PROC 416 420	CD30
#36	AnnotatorNotes T47	C3888510; CD30 expression; Laboratory Procedure
T48	PROC 484 488	CD30
#37	AnnotatorNotes T48	C3888510; CD30 expression; Laboratory Procedure
T49	PROC 723 727	CD30
#38	AnnotatorNotes T49	C3888510; CD30 expression; Laboratory Procedure
T50	PROC 926 930	CD30
#39	AnnotatorNotes T50	C3888510; CD30 expression; Laboratory Procedure
T40	PROC 527 543	Estado funcional
#40	AnnotatorNotes T40	C4525818; Clinical Performance Status; Health Care Activity | C3694602; functional status of patient; Therapeutic or Preventive Procedure
A1	Assertion T45 Negated
A2	Status T24 History_of
A3	Status T25 History_of
A4	Status T26 History_of
A5	Status T27 History_of
A6	Status T28 History_of
#41	AnnotatorNotes T6	C0282461; Phase 3 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product 
#42	AnnotatorNotes T14	C5238366; Measurable Lesion; Finding 
#43	AnnotatorNotes T25	C0376545; Hematologic Neoplasms; Neoplastic Process 
#44	AnnotatorNotes T43	C0521116; Current (present time); Temporal Concept 
T41	Observation 1088 1099	en remisión
A7	Assertion T41 Negated
#45	AnnotatorNotes T41	C0544452; Disease remission; Finding
R1	Negation Arg1:T44 Arg2:T41	
R2	Negation Arg1:T44 Arg2:T45	
R3	Has_Duration_or_Interval Arg1:T41 Arg2:T45	
R4	Combined_with Arg1:T1 Arg2:T2	
R5	Combined_with Arg1:T8 Arg2:T9	
R6	Combined_with Arg1:T8 Arg2:T7	
R7	Experiences Arg1:T39 Arg2:T5	
R8	Location_of Arg1:T29 Arg2:T5	
R9	Experiences Arg1:T39 Arg2:T4	
R10	Experiences Arg1:T39 Arg2:T3	
R11	Experiences Arg1:T39 Arg2:T1	
R12	Experiences Arg1:T39 Arg2:T46	
T51	Result_or_Value 178 187	positivos
#46	AnnotatorNotes T51	C1446409; Positive; Finding
R13	Has_Result_or_Value Arg1:T46 Arg2:T51	
R14	Location_of Arg1:T30 Arg2:T12	
T52	Result_or_Value 421 430	positivos
#47	AnnotatorNotes T52	C1446409; Positive; Finding
R15	Has_Result_or_Value Arg1:T47 Arg2:T52	
T53	Result_or_Value 489 498	positivos
#48	AnnotatorNotes T53	C1446409; Positive; Finding
R16	Has_Result_or_Value Arg1:T48 Arg2:T53	
R17	Location_of Arg1:T31 Arg2:T13	
T54	Result_or_Value 544 547	≤ 2
R18	Has_Result_or_Value Arg1:T40 Arg2:T54	
T55	CONC 568 572	ECOG
#49	AnnotatorNotes T55	C1520224; ECOG performance status; Intellectual Product
R19	Used_for Arg1:T55 Arg2:T40	
T56	Result_or_Value 641 646	≥ 1,5
R20	Has_Result_or_Value Arg1:T14 Arg2:T56	
T57	Observation 575 614	Avidez por la fluorodesoxiglucosa (FDG)
#50	AnnotatorNotes T57	C5239279; FDG-Avid Tumor; Finding (?)
R22	Experiences Arg1:T42 Arg2:T17	
R23	Location_of Arg1:T33 Arg2:T17	
T58	Result_or_Value 728 737	positivas
#51	AnnotatorNotes T58	C1446409; Positive; Finding
R24	Has_Result_or_Value Arg1:T49 Arg2:T58	
R25	Experiences Arg1:T42 Arg2:T49	
T59	Quantifier_or_Qualifier 673 690	nuevo diagnóstico
#52	AnnotatorNotes T59	C1518321; Newly Diagnosed; Qualitative Concept
R27	Overlap Arg1:T36 Arg2:T19	
R28	Overlap Arg1:T18 Arg2:T19	
R29	Location_of Arg1:T34 Arg2:T22	
R30	Location_of Arg1:T35 Arg2:T22	
T60	Result_or_Value 931 940	positivas
#53	AnnotatorNotes T60	C1446409; Positive; Finding
R31	Has_Result_or_Value Arg1:T50 Arg2:T60	
R32	Overlap Arg1:T20 Arg2:T43	
T61	Quantifier_or_Qualifier 1003 1011	invasora
#54	AnnotatorNotes T61	C0205281; Invasive; Qualitative Concept
R33	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T61	
A8	Status T61 History_of
R34	Before Arg1:T24 Arg2:T41	
R35	Before Arg1:T25 Arg2:T41	
R36	Before Arg1:T26 Arg2:T41	
#55	AnnotatorNotes T24	C0677930; Primary Neoplasm; Neoplastic Process
R26	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T59	
#56	AnnotatorNotes T36	C0154728; Meningeal disorder; Disease or Syndrome
A9	Experiencer T39 Patient
A10	Experiencer T42 Patient
